Oral Prednisolone Followed by Inhaled Budesonide in Newly Diagnosed Pulmonary Sarcoidosis*
|
|
- Brendan Lee
- 6 years ago
- Views:
Transcription
1 Oral Prednisolone Followed by Inhaled Budesonide in Newly Diagnosed Pulmonary Sarcoidosis* A Double-Blind, Placebo-Controlled Multicenter Study Anne Pietinalho, MD; Pentti Tukiainen, MD, PhD, FCCP; Tari Haahtela, MD, PhD; Tore Persson, PhD; Olof Selroos, MD, PhD, FCCP; and the Finnish Pulmonary Sarcoidosis Study Group Study objective: To evaluate the efficacy of oral prednisolone, followed by inhaled budesonide, in patients with newly diagnosed (< 3 months) stage I and stage II pulmonary sarcoidosis. Design: Double-blind, placebo-controlled, parallel-group, multicenter study. Setting: Twenty pulmonary medicine departments in Finland. Patients: One hundred eighty-nine adult patients were randomized to treatment. Patients with erythema nodosum or stage IV sarcoidosis (pulmonary fibrosis), and patients requiring immediate treatment with oral corticosteroids for extrapulmonary lesions or chronic illnesses were excluded. Treatment: The patients received either oral prednisolone for 3 months (20 mg/d for 8 weeks, 15 mg/d for 2 weeks, and 10 mg/d for 2 weeks) followed by inhaled budesonide (Pulmicort Turbuhaler; Astra Draco; Lund, Sweden) for 15 months at 800 g bid, or placebo tablets followed by placebo inhaler therapy. Measurements: Chest radiographs, lung volumes (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), serum angiotensin-converting enzyme (SACE), and 2 -microglobulin at 3-month intervals. Results: After 3 months of treatment, radiographic improvements were seen in the activetreatment group when compared to the placebo-treatment group. At 6 months, the difference was still statistically significant. Later, no differences were found. In patients with initial stage I lesions, neither the FVC nor the DLCO (the percent predicted mean values) changed during the study, as they were normal from the beginning. In patients with initial stage II disease, the difference in the FVC mean values between the groups also remained unchanged throughout the study. In stage II patients treated for 18 months, but not earlier, the difference in DLCO became statistically significant; the largest differences were seen in patients with initial FVC values < 80% of predicted and DLCO values < 75% of predicted. The decrease in SACE in the active-treated stage II patients was significantly larger than in the placebo-treated patients. No difference was observed in adverse events between the active-treated patients and the placebo-treated patients. Conclusion: Treatment is not required for patients with stage I disease. An initial treatment with prednisolone followed by long-term inhalation of budesonide is more effective than placebo in patients with stage II disease. Sequential oral and inhaled corticosteroid therapy may be an alternative treatment regimen for stage II sarcoidosis patients, rather than long-term oral corticosteroid therapy alone. (CHEST 1999; 116: ) Key words: angiotensin-converting enzyme; budesonide; chest radiograph; glucocorticosteroids; inhalation; lung volumes; prednisolone; sarcoidosis Abbreviations: Dlco diffusing capacity of the lung for carbon monoxide; pmdi pressurized metered-dose inhaler; SACE serum angiotensin-converting enzyme; VC vital capacity 424 Clinical Investigations
2 Sarcoidosis is a systemic granulomatous disease that usually affects the respiratory tract. The chest radiographs are classified on a five-grade scale: stage 0 (normal), stage I (bilateral hilar lymphadenopathy), stage II (parenchymal infiltrations with hilar lymphadenopathy), stage III (parenchymal lesions alone), and stage IV (pulmonary fibrosis). The natural course of sarcoidosis varies. Spontaneous recoveries occur in 40 to 80% of patients, but fibrosis with functional impairment may develop. 1,2 No test is available to determine the outcome for an individual patient at the time of diagnosis. Erythema nodosum is a symptom that usually indicates a good prognosis, 3,4 but preserved tuberculin skin test positivity, age 40 years, female gender, and absence of extrapulmonary lesions have also been associated with a good prognosis. 4 6 A widely accepted clinical routine for the management of patients with pulmonary lesions is to follow up symptom-free patients for 6 to 12 months in the hope of achieving a spontaneous recovery. If symptoms or lung function indicate deterioration, or if radiographic lesions progress during an observation period, treatment with glucocorticosteroids is started. 7 9 Oral corticosteroids are the most common agents used to treat sarcoidosis, and therapy usually results in an initial improvement in symptoms, radiographic findings, lung function, BAL findings, and 67 Ga uptake. 10 Increased enzyme activity, such as serum angiotensin-converting enzyme (SACE), and increased concentrations of serum lysozyme normalize during treatment with corticosteroids. 11 Relapses may be prevented with continuous low-dose corticosteriod treatment, 12 and even fibrotic changes may be prevented with aggressive corticosteriod treatment. 13 However, the side effects of oral corticosteroids, including weight gain, fluid retention, hyperglycemia, hypertension, osteoporosis, cataract, and glaucoma, greatly limit their use. Most clinical studies have shown that the long-term prognosis has not been influenced by corticosteriod treatment. 10 The *From Meltola Hospital (Drs. Pietinalho and Selroos), Karjaa, Finland; the Departments of Pulmonary Medicine (Dr. Tukiainen), and Allergic Diseases (Dr. Haahtela), University Central Hospital, Helsinki, Finland; and Astra Draco AB (Dr. Persson), Lund, Sweden. Dr. Persson is a full-time statistician employed by Astra Draco AB. Dr. Selroos, the author who initiated the study, has been appointed a medical advisor to Astro Draco AB. A complete list of the members of the Finnish Sarcoidosis Study Group is given in the Appendix. Financial support and all blinded study medication were provided by Astra Draco AB, Lund, Sweden. Manuscript received September 29, 1998; revision accepted February 24, Correspondence to: Olof Selroos, MD, FCCP, Solvegatan 3A, S Lund, Sweden; olof.selroos@draco.se.astra.com poor long-term effect of corticosteroids in controlled clinical studies may be a result of the adopted follow-up strategy. The patients included in these studies may have had their pulmonary lesions far too long to respond to corticosteroids. It is unknown whether the long-term outcome would be different if treatment had been started earlier, eg, immediately after diagnosis. The duration of treatment may vary: it may last months, or it may be lifelong. The side effects of oral corticosteroids often cause problems. Inhaled corticosteroids have a different and more favorable safety profile. 14 However, only a few studies (some without a proper control group) have evaluated the effects of inhaled corticosteroids in pulmonary sarcoidosis; some clinical efficacy has been shown, and cellular findings in BAL fluid have changed, 19,20 indicating beneficial effects of the treatment. Inhaled budesonide is taken up in the lung parenchyma in sufficient concentrations to ensure good receptor binding, 21,22 and the risk of side effects is low when compared to the risks associated with oral corticosteroids. 14 Consequently, if it is shown to be effective, treatment with budesonide could be started early, instead of waiting and hoping for a spontaneous recovery (the standard follow-up). The ethical dilemma is that some patients would probably be treated unnecessarily. We performed an 18-month, double-blind, placebo-controlled study with prednisolone, followed by budesonide, in patients with newly diagnosed radiographic stage I and stage II pulmonary sarcoidosis. The patients could be symptom-free and have normal lung function; therefore, no established clinical indications for starting treatment were required. A future aim is to follow these patients for a total of 5 years to evaluate whether early treatment with prednisolone followed by budesonide influences the 5-year prognosis of pulmonary sarcoidosis. Study Design Materials and Methods The study was a randomized, placebo-controlled, double-blind, parallel-group study with two treatment groups: the activetreatment group received oral prednisolone for 3 months, followed by inhaled budesonide (Pulmicort Turbuhaler; Astra Draco; Lund, Sweden) for 15 months; and the placebo-treatment group received an oral placebo for 3 months, followed by an inhaled placebo for 15 months. Randomization was performed separately at each center in blocks of four. The 20 pulmonary medicine departments located all over Finland included consecutive patients over a period of 3.5 years. Patients Sarcoidosis patients of either gender and 18 years old were included. They all had newly detected (diagnosed within 3 CHEST / 116 / 2/ AUGUST,
3 months from the first symptoms or signs) radiographic stage I or stage II pulmonary sarcoidosis, with a typical clinical picture of sarcoidosis. Other lung diseases were carefully excluded. A positive tissue biopsy or cytological finding, increased SACE activity, or a positive Kveim test was desirable, but not obligatory. The exclusion criteria were erythema nodosum, because of its generally good prognosis, and obvious pulmonary fibrosis. Patients with extrapulmonary sarcoidosis who required immediate treatment with oral corticosteroids or patients receiving treatment with corticosteroids for some other reason were also excluded, as were pregnant and lactating women, and patients with other specified, poorly controlled diseases. Protocol Active treatment consisted of oral prednisolone (20 mg/d for 8 weeks, 15 mg/d for 2 weeks, and 10 mg/d for 2 weeks) or corresponding placebo tablets. The active-treatment group then received budesonide via an inspiratory flow-driven, multidose, dry-powder 400- g inhaler at two inhalations bid (a daily dose of 1,600 g) for 15 months. The patients who were treated with placebo tablets continued with a placebo inhaler. The patients visited the clinics every third month during the 18-month treatment period. The clinical picture, chest radiographs, lung function tests (spirometry, diffusing capacity of the lung for carbon monoxide [Dlco]), SACE (Lieberman s modification of Cushman s method; reference value, 22 to 70 U/mL), serum and urinary calcium, as well as serum 2 -microglobulin (Phadebas 2 -Microtest; Pharmacia AB; Uppsala, Sweden) were monitored during the study. Serum cortisol levels were checked (Amerlex Radioimmunoassay; Amersham International; Amersham, UK) at the beginning of the study and at the 12-month visit. All tests and measurements were performed at the participating centers with the methods locally used. A patient was defined as a treatment failure and was withdrawn from the study if symptoms developed that were severe enough to interfere with daily life activities, if there was an objective deterioration in radiographic findings, or if there was a decrease 15% in FVC or 20% in Dlco compared to baseline values. Also, the patient was withdrawn if defined extrathoracic manifestations of sarcoidosis developed that required systemic treatment with corticosteroids. The chest radiographs taken at each clinic visit were interpreted by the local chest physician/radiologist and were classified as stage 0, I, II, or III. They were then compared to the patient s first chest radiograph and were classified as normalized (score 0), improved (score 1), unchanged (score 2), or deteriorated (score 3). Decisions to be made on radiographic grounds during the study were based on these interpretations. After the study, all of the changes in chest radiographs were evaluated blindly by an independent radiologist and were categorized into six defined groups: normal, markedly improved, slightly improved, unchanged, slightly deteriorated, and markedly deteriorated (scores 0 to 5). The final stage was also reported (stage 0, I, II, or III). At all clinic visits, the patients were asked whether any health problems or drug-related side effects had occurred since the previous visit. If any drug-related side effects had occurred, the responsible physician decided whether or not to withdraw the patient from the study. Also, the patient could leave the study at his or her own request, or could be withdrawn if poor compliance was observed. Ethical Requirements and Good Clinical Practice Guidelines The ethics committee at each study center approved the study protocol before any study-related procedures were undertaken. The study was monitored according to the Good Clinical Practice guidelines for the Nordic countries. All of the patients received thorough information about the study, and written informed consent was obtained in all cases. The study was monitored by clinical research assistants from Meltola Hospital. Statistical Analysis The primary analyses in the study are based on an all-patientstreated approach. The last value-extended principle was applied from visit 3 to visit 7, but not from visit 2, as this was the point in time when the treatment was changed from oral to inhaled medication (for visits see Table 1). The analyses were performed using t tests and analysis of variance. Separate analyses were done to investigate the influence of the initial stages (I and II) on the outcome. In all analyses, a statistically significant level refers to p values Results A total of 190 patients were included in the study, and 189 of them were randomized to treatment. The diagnosis of sarcoidosis was made based on clinical symptoms and signs, as well as on chest radiographic findings. The diagnosis was supported by a positive tissue biopsy finding in 92 patients and by a positive fine-needle aspiration cytology finding in 23 patients. A Kveim test was positive in 3 patients, and 67 patients had an elevated SACE value at diagnosis. Table 1 Flow Chart of the Study* Tests Visit 1, 0 mo Visit 2, 3 mo Visit 3, 6 mo Visit 4, 9 mo Visit 5, 12 mo Visit 6, 15 mo Visit 7, 18 mo Chest radiograph x x x x x x x Spirometry x (x) (x) (x) x (x) x Diffusion capacity x (x) (x) (x) x (x) x SACE x x x x x x x S 2 -microglobulin x x x x x x x S calcium x (x) (x) (x) (x) S cortisol x x U calcium x (x) (x) (x) (x) (x) (x) U cortisol x U creatinine x *x performed; (x) performed only if initial value abnormal; S Serum; U Urinary. 426 Clinical Investigations
4 Randomization resulted in 92 patients in the active-treatment group and 97 patients in the placebotreatment group. There were no statistically significant differences between the groups at baseline for gender and age distribution, smoking habits, symptoms, or chest radiographic stage. The patient characteristics are presented in Table 2. Thirty-five patients (16 in the active-treatment group and 19 in the placebo-treatment group) did not complete the study. The reasons for discontinuation are presented in Table 3. Sixteen patients were withdrawn because of treatment failure. Of these 16 patients, 10 placebo-treated patients were withdrawn after a mean of 176 study days (range, 44 to 385 days; median, 181 days) and 6 active-treated patients were withdrawn after a mean of 315 days (range, 111 to 463 days; median, 332 days). Radiographic Findings All patients had chest radiographs taken at the start of the study and every third month during the study; therefore, up to 7 chest radiographs per patient were taken, and a total of 1,170 radiographs were examined. The agreement between the local radiologist and the independent radiologist with respect to the interpretation of the radiographic stages was highly significant ( 0.513; p 0.001). The results based on the former evaluations are presented. In the interpretation of the radiographic stage at entry, no statistically significant difference was found between the local investigators and the independent observer, although more patients were classified by the independent observer as being at stage III at entry (n 24) than were classified by the local investigator (n 10). In both treatment groups, the proportion of patients at radiographic stage I at entry was around 50% (budesonide group, 52%; placebo group, 47%). Table 2 Patient Characteristics* Table 3 Patients Discontinuing During the Study* Reasons In patients with initial stage I disease (n 94), a significant difference between the groups was seen after treatment for 3 months (p 0.003) and 6 months (p 0.013), but not thereafter. In patients with initial stage II disease, no differences between the groups were seen during the entire study period. The improvements of the chest radiographs in the entire series of patients is shown in Figure 1. A statistically significant difference between the genders was seen, with female patients having higher scores (eg, more lesions) than the male patients after treatment for 15 months (p 0.03) and 18 months (p 0.04). Patient age was also an influential factor: increased age was associated with significantly higher scores after treatment for 9 months (p 0.04), 15 months (p 0.03), and 18 months (p 0.02). Lung Function Tests Prednisolone Followed by Budesonide Placebo Withdrawn consent 2 5 Adverse events 2 1 Treatment failure 6 10 Poor compliance 4 1 Other reasons 2 2 Total *Values given as No. of patients. FVC, FEV 1, and Dlco were registered as absolute values and as percent of predicted values. The differences between the active-treatment group and the placebo-treatment group were consistent when comparing the results, both in absolute numbers and in percent of predicted values. FVC: The FVC values at baseline, after 3 months of prednisolone treatment, and at 18 months are Patient Characteristics Prednisolone Followed by Budesonide Placebo Gender Male Female Total Age, yr Smokers Ex-smokers Stage I Stage II Stage III 6 5 Duration of disease, d Symptom-free *Values expressed as No. of patients or mean SD. Figure 1. The progression of chest radiographic findings over 18 months for the entire study population. CHEST / 116 / 2/ AUGUST,
5 shown in Table 4. No significant difference was found between active-treated patients and placebotreated patients with initial stage I disease. In patients with initial stage II disease, the FVC improved from baseline to 18 months on average by 0.15 L (4.56 to 4.71 L) in the active-treatment group, but remained the same (4.13 to 4.12 L) in the placebotreatment group. The difference was not statistically significant (p 0.39). However, when considering patients with an initial FVC 80% of predicted values, the active-treated patients (n 10) improved by %, whereas the placebo-treated patients (n 13) improved by %. This difference was almost statistically significant (p 0.057). DLCO: The Dlco mean values at baseline and after treatment for 3 months and 18 months are shown in Table 4. A significant difference between the active-treated patients and the placebo-treated patients was found after treatment for 3 months (p 0.010) and 6 months (p 0.020). At 18 months, the difference was almost significant (p 0.052). In stage II patients treated for 18 months, but not earlier, the difference in Dlco became statistically significant; the largest differences were seen in patients with an initial Dlco 75% of predicted values. Laboratory Test Values SACE: Treatment with corticosteroids resulted in a rapid decrease in mean SACE activity. A spontaneous gradual decrease in SACE occurred in the placebo-treatment group. After treatment for 18 months, no significant difference was found between the active-treated patients and the placebo-treated patients (for all patients and for patients with initial stage I disease; see Table 4). However, in patients with initial stage II disease, there was an almost significant difference between the groups at 3 months of treatment with prednisolone (p 0.058), but a significant difference at 6 months (p 0.014). This difference remained statistically significant throughout the study period (Fig 2). Serum 2 -Microglobulin and Serum and Urinary Calcium: No significant differences were observed between the two study groups in serum 2 -microglobulin or calcium concentrations or in the 24-h excretion of calcium in urine. Serum Cortisol: The serum cortisol values were measured at the beginning of the study and after 12 months of treatment. There was a statistically significant decrease in mean ( SD) cortisol values in the active-treatment group ( to nmol/l) as compared with the placebo-treatment group ( to nmol/l). The difference between the changes was statistically significant (p 0.002). All individual cortisol values except those for 2 patients in the placebo-treatment group and 11 patients in the active-treatment group remained within the normal reference range. The difference in serum cortisol mean values was also reflected in a difference in 24-h urinary cortisol values (active-treatment group, to Table 4 FVC and DLCO and SACE Activities After Treatment With Prednisolone Followed by Budesonide or With Placebo* Prednisolone Followed by Budesonide Placebo Patient Data No. of Patients FVC, % predicted Dlco, % predicted SACE, U/mL No. of Patients FVC, % predicted Dlco, % predicted SACE, U/mL All patients Baseline (13.8) 97.4 (17.4) 79 (74) (12.2) 95.2 (15.4) 75 (72) 3 mo (13.9) 98.8 (18.3) 46 (52) (13.4) 97.0 (18.2) 60 (50) 18 mo (12.3) (15.8) 59 (65) (13.5) 96.8 (16.2) 59 (58) Stage I patients Baseline (13.8) (18.4) 61 (54) (12.3) 98.0 (16.2) 65 (63) 3 mo (15.7) (17.9) 41 (45) (13.9) (17.6) 57 (50) 18 mo (12.2) (14.7) 57 (71) (12.3) 98.2 (14.1) 49 (36) Stage II patients Baseline (14.4) 95.8 (15.8) 91 (77) (11.8) 92.2 (14.4) 85 (79) 3 mo (11.8) 97.1 (18.1) 51 (64) (11.9) 92.5 (18.0) 65 (52) 18 mo (11.8) (14.8) 57 (69) (14.4) 95.0 (16.1) 72 (75) *Values given as mean SD. p p p Clinical Investigations
6 Figure 2. The changes in mean ( SEM) values over 18 months in stage II patients treated with corticosteroids or placebo. Statistically significant differences between the groups are shown: * p 0.05; ** p 0.01; *** p nmol/24 h; placebo-treatment group, to nmol/24 h; difference, p 0.007). Discussion We report the results of 3 months of double-blind, randomized treatment with oral prednisolone or placebo, followed by 15 months of treatment with inhaled budesonide or placebo in patients with newly detected pulmonary sarcoidosis. The aim was to evaluate the efficacy of this treatment. However, it was decided to follow the patients for 5 years to see whether this early treatment could influence the prognosis of the disease. Ninety-four stage I patients, 84 stage II patients, and 11 stage III patients were included in the study. At inclusion, both patient groups already had normal mean values for FVC and Dlco. It is well known that spontaneous recoveries are common in sarcoidosis, 1 4 especially in patients having the acute type of sarcoidosis with erythema nodosum, arthralgia, and fever. 1,2 The radiographic and functional improvements in the placebo-treated patients in this study were great, surpassing the improvements seen in a previous study in Finland. 23 The spontaneous recoveries were especially frequent in patients with initial stage I chest radiographs. The reason for including the patients with stage I disease in the study, however, was to evaluate the 5-year prognosis, not just the immediate treatment effect. This 5-year follow-up study is underway. When evaluating the effects of treatment in patients with initial stage II chest radiographic findings, the results are different. Although no significant difference between the groups could be found for radiographic developments, a difference in favor of steroid treatment was observed for Dlco values and SACE activity. The most striking difference between the treatment groups was found in patients with initial FVC values 80% of predicted and initial Dlco values 75% of predicted. This indicates that an initial 3-month course of oral prednisolone followed by a 15-month course of inhaled budesonide is a clinically effective treatment regimen for patients having a clinical indication for starting treatment with corticosteroids. The indication could be a restrictive abnormality in lung function tests in combination with increased SACE activity. It is obvious that a third treatment group (a group receiving prednisolone for 3 months and placebo thereafter) would have been of interest. Now it remains unclear as to what extent the documented effects of corticosteroid treatment are due to the 3-month intervention with oral prednisolone. However, a 3-month course of oral steroids has not been considered to give stable and persisting treatment results. 13 It was also noted that in stage II patients SACE values had not returned to normal during treatment with prednisolone, but did so during the later treatment with budesonide. The same trend was true of lung function tests, although not always statistically significantly different from placebo treatment. Treatment with prednisolone, followed by budesonide, resulted in a statistically significant effect on serum and urinary cortisol mean values; however, very few of the individual values decreased to levels below the lower limit of the reference range, and the finding is probably not very important clinically. The side effects normally associated with systemic corticosteroid activity were not seen during the duration of the study. When this study was initiated, it was known that single 1.6-mg doses of budesonide given to patients immediately before general anesthesia for thoracic surgery resulted in peripheral lung tissue concentrations of budesonide high enough to bind to glucocorticosteroid receptors and give an anti-inflammatory effect. 22 Placebo-controlled studies in patients with active sarcoidosis using budesonide, 1.6 mg/d, showed changes in BAL cell findings consistent with beneficial effects. 19,20 It was pertinent to expect that these changes could favorably influence the pathogenic mechanisms in pulmonary sarcoidosis. In a prior study of 20 stage II to stage III sarcoidosis patients who did not improve spontaneously, openly given budesonide, 1.2 to 1.6 mg/d, seemed to diminish radiographic infiltrations, decrease SACE activity, and improve FVC values. 15 A number of patients who were treated with oral corticosteroids and relapsed after stopping the treat- CHEST / 116 / 2/ AUGUST,
7 ment showed significant improvements with inhaled budesonide alone. 24 In such cases, spontaneous remissions rarely occur. An oral corticosteroid-sparing effect of budesonide was reported in patients with chronic pulmonary sarcoidosis. 25 When starting this study, we were aware of two double-blind studies that had been initiated but not completed. Both studies have now been reported. In the study by Zych et al, patients with stage II to stage III disease received an initial 6-week course of oral steroids. Thereafter, they were randomized to treatment with budesonide, 1.6 mg/d, or oral prednisolone, 10 mg/d. The study lasted for 12 months. No differences were found between the two maintenance treatments. Alberts et al 18 included 47 patients with stage I to stage III disease in a doubleblind, placebo-controlled study. At entry, the patients had abnormal lung function values (vital capacity [VC], 79% of predicted; Dlco, 77% of predicted) or 20% lymphocytes in the BAL fluid (in stage II to stage III patients). Treatment consisted of budesonide, 1.2 mg once daily, or placebo for 6 months. A 6-month observation period without treatment followed. When compared to treatment with the placebo, budesonide treatment resulted in a significant increase in VC and in better subjective symptom control. However, both these studies were performed in patients who had had sarcoidosis for a considerable period of time. Therefore, we decided to include only patients who had had a diagnosis of sarcoidosis for 3 months. The results in stage II patients in our study are in agreement with the results of Zych et al 17 and Alberts et al, 18 showing beneficial effects during maintenance treatment with budesonide. However, this was not reported to be the case in a smaller study with several subgroups by Milman et al. 26 Although they found an obvious increase in VC, the difference in change between the steroid-treated patients and placebo-treated patients was not statistically significant. Clinical experience with budesonide as an initial treatment has indicated that functional and radiographic improvements develop gradually, but more slowly than improvements seen with high doses of oral steroids. 15 The induction treatment should therefore probably consist of oral corticosteroids, and budesonide should be regarded as an oral corticosteroid-sparing agent during long-term maintenance treatment. The more favorable side-effect profile of budesonide (compared to that of oral corticosteroids) should be considered when deciding on a maintenance treatment. It should be noticed, however, that the reported study (as well as other studies 17,18 showing efficacy with budesonide) was performed in white patients, who have a better overall prognosis than African-American patients. 2 In this study, a significant difference was observed between the active-treated patients and the placebotreated patients for serum and urinary cortisol mean values. When the study started, a budesonide drypowder inhaler (Pulmicort Turbuhaler; Astra Draco) was considered equieffective with a budesonide pressurized metered-dose inhaler (pmdi). However, later studies 27 documented a pulmonary deposition via a Turbuhaler that was twice as high as the pulmonary deposition via a pmdi. Therefore, the dosage of budesonide given in this study, 1,600 g/d, may have been approaching a daily dosage of 3,200 g as administered via a pmdi. This dosage is not recommended for clinical use and is associated with systemic corticosteroid activity. 28 It is, of course, unknown whether a lower dose of budesonide administered via a Turbuhaler would have produced the same degree of clinical improvement. Further double-blind, controlled studies are warranted. These studies should concentrate on patients with newly detected stage II to stage III disease, but with an impaired lung function. As a group, patients with stage I disease can be followed up without treatment in the hope of spontaneous recovery. ACKNOWLEDGMENTS: The authors thank Ilkka Salven, MD, Meltola Hospital, for performing the blinded evaluation of all chest radiographs, and Inge-Maj Enberg, RN, Auli Lindholm, RN, Ann-Britt Löfroos, CRA, and Eeva-Leena Franicevic, RN, Meltola Hospital, for monitoring the study. Appendix In addition to the authors, the following hospitals and investigators were members of the Finnish Pulmonary Sarcoidosis Study Group and participated in the study: Etelä-Karjala Central Hospital (R. Kauppinen); Etelä-Pohjanmaa Central Hospital (M. Koskenkari, E. Kokko, L. Tuomisto); Härmä Hospital (E. Aalto); Kanta-Häme Central Hospital (M. Järvinen); Keski-Pohjanmaa Central Hospital (R. Lillqvist, J-H. Slotte); Kiljava Hospital (R. Tammivaara, S. Koskinen); Kuopio University Hospital and Tarina Hospital (R. Majander); Kymenlaakso Central Hospital (M. Havu); Laakso Hospital (A. Ahonen, P. Saarelainen); Lappi Central Hospital (O. Säynäjäkangas); Länsi-Pohja Central Hospital (J. Kotaniemi); Oulu University Central Hospital (T. Keistinen, O. Rossi); Pietarsaari Hospital, Östanlid Department (J. Jaakkola); Pohjois-Karjala Central Hospital (E. Perämäki); Satalinna Hospital (V. Tuominen, S. Paloheimo, M. Saarelma); Savonlinna Central Hospital (K. Venho); Tampere University Central Hospital and Pikonlinna Hospital (M. Nieminen); Turku University Central Hospital and Paimio Hospital (A. Palojoki, P. Laurinen); and Vaasa Central Hospital (T. Rinne, L. Lammi). References 1 Selroos O. The frequency, clinical picture and prognosis of pulmonary sarcoidosis in Finland. Acta Med Scand 1969; 503(suppl): Clinical Investigations
8 2 Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57: Löfgren S. Primary pulmonary sarcoidosis: II. Clinical course and prognosis. Acta Med Scand 1953; 145: Hannuksela M, Salo OP, Mustakallio KK. The prognosis of acute untreated sarcoidosis. Ann Clin Res 1970; 2: Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 208: Tukiainen P, Taskinen E, Riska H. The prognostic value of bronchoalveolar lavage in sarcoidosis. Sarcoidosis 1994; 11: DeRemee RA, Offord KP. The treatment of pulmonary sarcoidosis: the house revisited. Sarcoidosis 1992; 9(suppl 1): Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149: Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: Selroos O. Glucocorticosteroids and pulmonary sarcoidosis. Thorax 1996; 51: Grönhagen-Riska C, Selroos O, Niemistö M. Angiotensin converting enzyme: V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis 1980; 61: Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 1987; 165: Scadding M, Mitchell DN. Sarcoidosis. London, UK: Chapman and Hall, 1985; Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma [review]. Am Rev Respir Dis 1993; 148:S1 S26 15 Selroos O. Use of budesonide in the treatment of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465: Selroos O, Löfroos AB, Pietinalho A, et al. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11: Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10: Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebocontrolled study. Eur Respir J 1995; 5: Erkkilä S, Fröseth B, Hellström PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5: Spiteri MA, Newman SP, Clarke SW, et al. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 1989; 2: Ryrfeldt Å, Persson G, Nilsson E. Pulmonary disposition of the potent glucocorticoid budesonide, evaluated in an isolated perfused rat lung model. Biochem Pharmacol 1989; 38: Van den Bosch JM, Westermann CJ, Aumann J, et al. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993; 14: Selroos O, Niemistö M, Riska N. A follow-up of treated and untreated early pulmonary sarcoidosis. In: Iwai K, Hosoda Y, eds. Proceedings of the VI International Conference on Sarcoidosis. Tokyo, Japan: University of Tokyo Press, 1973: Selroos O. Use of budesonide in the treatment of pulmonary sarcoidosis. In: Ellul-Micallef R, Lam WK, Toogood JH, eds. Advances in the use of inhaled corticosteroids. Hong Kong: Exerpta Medica, 1987: Morgan AD, Johnson MA, Kerr I, et al. The action of an inhaled corticosteroid as a steroid sparing agent in chronic pulmonary sarcoidosis [abstract]. Am Rev Respir Dis 1987; 135:A Milman N, Graudal N, Grode G, et al. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236: Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler P-MDI. Eur Respir J 1994; 7: Johansson SÅ, Andersson KE, Brattsand R, et al. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis Suppl 1982; 122:74 82 CHEST / 116 / 2/ AUGUST,
Long-Term Use of Corticosteroid Eye Drops Delays the Spontaneous Remission of Pulmonary Sarcoidosis
Tohoku J. Exp. Med., 2004, Topical 202, Steroid 275-282 Therapy Delays the Remission of Sarcoidosis 275 Long-Term Use of Corticosteroid Eye Drops Delays the Spontaneous Remission of Pulmonary Sarcoidosis
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationCLINICAL VIGNETTE Sarcoidosis: A Case Study Gloria Kim, M.D.
CLINICAL VIGNETTE Sarcoidosis: A Case Study Gloria Kim, M.D. Case Report A 56-year-old female presented to her primary care physician with complaints of dyspnea on exertion and increasing cough. She reported
More informationL. Thorsson, S. Edsbäcker, T-B. Conradson
Eur Respir J, 1994, 7, 1839 1844 DOI: 10.1183/09031936.94.07101839 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 0903-1936 Lung deposition of budesonide
More informationStarting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment
Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment THYS van der MOLEN, BETTY MEYBOOM-DE JONG, HELMA H. MULDER, and DIRKJE S. POSTMA Department of General Practice,
More informationDefining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
Original article: clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2011; 28; 56-64 Mattioli 1885 Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
More informationRandomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study
Eur Respir J 1999; 13: 1345±1350 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Randomized trial of inhaled fluticasone propionate in chronic
More informationLate-onset and Rare Far-advanced Pulmonary Involvement in Patients with Sarcoidosis in Taiwan
Sarcoidosis in Taiwan ORIGINAL ARTICLE Late-onset and Rare Far-advanced Pulmonary Involvement in Patients with Sarcoidosis in Taiwan Chia-Wei Hsieh, 1 Der-Yuan Chen, 1 Joung-Liang Lan 1,2 * Background:
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationinhaled fluticasone propionate in healthy volunteers
Br J clin Pharmac 1994; 38: 521-525 An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers A. GRAHNEN, S.-A. ECKERNAS, R. M. BRUNDIN & A. LING-ANDERSSON
More informationAs-needed (intermittent) inhaled corticosteroid for mild asthma
1 3.2.2008 CIPP VIII 8 th International Congress on Pediatric Pulmonology, Nice 2008 As-needed (intermittent) inhaled corticosteroid for mild asthma Tari Haahtela, Professor Skin and Allergy Hospital,
More informationmeasured Improvement in am PEFR FP vs BUD gave +11l/min FP vs BDP gave nonsignificant improvement in PEFR +3l/min FP: BUD ratio 1.
1 of 8 09/05/2018, 11:29 Guideline topic: Pharmacological management of asthma Evidence table 4.25: Budesonide vs Beclomethasone Different inhaled corticosteroids (ICS) flixotide propionate (FP) vs budesonide
More informationEffect of disease duration on dose response of inhaled budesonide in asthma
Respiratory Medicine (2008) 102, 1065 1072 Effect of disease duration on dose response of inhaled budesonide in asthma Olof Selroos a,b, a Mjölbolsta Hospital, Karis, Finland b SEMECO AB, Skogsvägen 5,
More informationProlonged treatment of pulmonary sarcoidosis
Thorax (1967), 22, 519. Prolonged treatment of pulmonary sarcoidosis with corticosteroids CLIFFORD HOYLE, HUGH SMYLLIE1, AND DAVID LEAK From King's College Hospital, London The results are described of
More informationPrincipal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report.
(For national authority SYNOPSIS use only) Date 3 March 2005 An open, randomized, two-way crossover study evaluating the pharmacokinetics of budesonide and formoterol from Symbicort pmdi versus Oxis Turbuhaler
More informationReport Finnish Registry for Kidney Diseases. Mortality of transplantation patients. Mortality of RRT patients according to diagnosis
Finnish Registry for Kidney Diseases Report Deaths/ patient-years 1 1 Mortality of transplantation patients 1 1 1 Mortality of RRT patients according to diagnosis Deaths/ patient-years 1 1 1 NIDDM Amyloidosis
More informationCorrespondence: C-G. Löfdahl Dept of Respiratory Medicine and Allergology University Hospital S Lund Sweden.
Eur Respir J 1997; 10: 2474 2478 DOI: 10.1183/09031936.97.10112474 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Differences in bronchodilating
More informationEffect of 1 year daily treatment with 400 µg budesonide (Pulmicort Turbuhaler ) in newly diagnosed asthmatics
Eur Respir J 1997; 10: 2210 2215 DOI: 10.1183/09031936.97.10102210 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of 1 year daily
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationThe treatment of pulmonary sarcoidosis
Eur Respir J 2013; 41: 1424 1438 DOI: 10.1183/09031936.00060612 CopyrightßERS 2013 SERIES SARCOIDOSIS FROM BENCH TO BEDSIDE Edited by V. Cottin and J. Müller-Quernheim Number 5 in this Series Established
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationChest radiograph of an. asymptomatic man. Case report. Case history
Eleftheria Chaini 1, Niki Giannakou 2, Dimitra Haini 3, Anna Maria Athanassiadou 4, Angelos Tsipis 4, Nikolaos D. Hainis 5 elhaini@otenet.gr 1 Pulmonary Dept, Corfu General Hospital, Kontokali, Greece.
More informationL. Borgström*, E. Bondesson*, F. Morén**, E. Trofast*, S.P. Newman +
Eur Respir J, 1994, 7, 69 73 DOI: 10.1183/09031936.94.07010069 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 0903-1936 Lung deposition of budesonide
More informationFeatures of sarcoidosis associated with chronic disease
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2014; 31; 275-281 Mattioli 1885 Features of sarcoidosis associated with chronic disease Robert P. Baughman, Elyse E.
More informationReport Finnish Registry for Kidney Diseases. Proportion of patients reaching treatment target (%) 100. Healthcare districts Regions
Finnish Registry for Kidney Diseases Proportion of patients reaching treatment target (%) 100 90 80 70 60 50 40 30 20 10 0 Healthcare districts Regions Finnish Registry for Kidney Diseases Contents Finnish
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationFinnish Registry for Kidney Diseases Report 2001
Finnish Registry for Kidney Diseases Report 2001 Contents Finnish Registry for Kidney Diseases 2001...ii Board of the Finnish Registry for Kidney Diseases...iii The Finnish population and its distribution
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationComparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic
Thorax 1984;39:340-344 Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma RICHARD F WILLEY, RONALD J FERGUSSON, DAVID J GODDEN, GRAHAM K CROMPTON,
More informationHYPERSENSITIVITY PNEUMONITIS
HYPERSENSITIVITY PNEUMONITIS A preventable fibrosis MOSAVIR ANSARIE MB., FCCP INTERSTITIAL LUNG DISEASES A heterogeneous group of non infectious, non malignant diffuse parenchymal disorders of the lower
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationThirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma
Asthma and lower airway disease Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma Tari Haahtela, MD, PhD, a Klaus Tamminen, MD, a Tuomo Kava, MD, PhD,
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationFamilial sarcoidosis in Finland and Hokkaido, Japan a comparative study
RESPIRATORY MEDICINE (1999) 93, 408 412 Familial sarcoidosis in Finland and Hokkaido, Japan a comparative study A. PIETINALHO*, M. OHMICHI,M.HIRASAWA,Y.HIRAGA, A-B. LÖFROOS* AND O. SELROOS* *Mjölbolsta
More informationConcise Review for Primary-Care Physicians
Concise Review for Primary-Care Physicians Sarcoidosis RICHARD A. DEREMEE, M.D. Sarcoidosis is a systemic granulomatous process of unknown cause. Pathologically, it is characterized by noncaseous granuloma,
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationInternational co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria.
Drug product: SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0681 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0681 Date: 24 Oktober, 2003 (For national
More informationPotency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler)
Respiratory Medicine (2007) 101, 610 615 Potency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler) Björn Ställberg a, Eva Pilman b, Bengt-Eric Skoogh c,, Bengt Arne Hermansson
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationEffect of inhaled budesonide therapy on lung function in schoolchildren born preterm
RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationPrognosis of cryptogenic fibrosing alveolitis
P TUKIAINEN, E TASKINEN, P HOLSTI, 0 KORHOLA, AND M VALLE Thorax 1983;38:349-355 From the Departments of Pulmonary Diseases, Oncology, and Diagnostic Radiology, University Central Hospital ofhelsinki,
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationPulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
More informationPackage ICSpkTS. R topics documented: September 4, Type Package
Package ICSpkTS September 4, 2012 Type Package Title Simulation of pharmacokinetic trials after administration of inhaled corticosteroids. Version 1.0 Date 2012-09-04 Author Benjamin Weber Maintainer Benjamin
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationTriennial Pulmonary Workshop 2012
Triennial Pulmonary Workshop 2012 Rod Richie, M.D., DBIM Medical Director Texas Life Insurance Company, Waco, TX EMSI, Waco, TX Lisa Papazian, M.D., DBIM Assistant Vice President and Medical Director Sun
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationRole of Serum Angiotensin Converting Enzyme in Sarcoidosis
Role of Serum Angiotensin Converting Enzyme in Sarcoidosis Pages with reference to book, From 131 To 133 Aysha H. Khan,Farooq Ghani,Mohammad Khurshid ( Departments of Pathology, The Aga Khan University
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationSystemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder
Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder L. Thorsson, 1,2 O. Borgå 2 & S. Edsbäcker 1,2 1 Department
More informationDaily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study)
See Perspective, p 644 1 Department of Allergy, Helsinki University Hospital, Finland; 2 AstraZeneca R&D, Lund, Sweden Correspondence to: Dr M Turpeinen, Skin and Allergy Hospital, Department of Allergy,
More informationAerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
More informationReport Finnish Registry for Kidney Diseases. Number of patients at end of year y y. 5 9 y. 0 4 y
Finnish Registry for Kidney Diseases Number of patients at end of year 14 13 12 11 1 9 8 7 6 5 4 3 2 1-9 -95 - -5-1 15 19 y 1 14 y 5 9 y 4 y Finnish Registry for Kidney Diseases Contents Finnish Registry
More informationHigh or standard initial dose of budesonide to control mild-to-moderate asthma?
Eur Respir J 2001; 17: 856 862 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 High or standard initial dose of budesonide to control mild-to-moderate
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationSarcoidosis Registry Proforma
Patient Demographics Patient Data Has a patient consent form been completed? 1.1 Title Mr 1.2 1.3 Forename(s) PlainText Surname PlainText 1.4 Gender Male 1.5 1.6 1.7 1.8 1.9 Mrs Ms Miss Dr Other
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationSarcoidosis: the clinical problem
Postgraduate Medical Journal (1988) 64, 531-535 Sarcoidosis: the clinical problem Edmund Neville St Mary's Hospital, Portsmouth P03 6AD, UK. Summary: This paper reviews the clinical manifestations of acute
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSarcoidosis is a disease of unknown aetiology, Childhood sarcoidosis: long-term follow-up. N. Milman* and A.L. Hoffmann #
Eur Respir J 2008; 31: 592 598 DOI: 10.1183/09031936.00011507 CopyrightßERS Journals Ltd 2008 Childhood sarcoidosis: long-term follow-up N. Milman* and A.L. Hoffmann # ABSTRACT: The aim of the present
More informationComparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
More informationBlood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement
Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationBudesonide equivalent dosing
Budesonide equivalent dosing dosage, adverse reactions, pharmacology and more. Budesonide 0.5mg Nebuliser Suspension (Breath Ltd) - Summary of Product Characteristics (SmPC) by Actavis UK Ltd 11-9-2012
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationSarcoidosis is a systemic granulomatous. Epidemiology of sarcoidosis in Japan
Eur Respir J 2008; 31: 372 379 DOI: 10.1183/09031936.00075307 CopyrightßERS Journals Ltd 2008 Epidemiology of sarcoidosis in Japan T. Morimoto*, A. Azuma*, S. Abe*, J. Usuki*, S. Kudoh*, K. Sugisaki #,
More informationPULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.
PULMONARY MEDICINE BOARD REVIEW Christopher H. Fanta, M.D. Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Financial Conflicts of Interest
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationORIGINAL INVESTIGATION. Effects of High-Dose Inhaled Corticosteroids on Plasma Cortisol Concentrations in Healthy Adults
Effects of High-Dose Inhaled Corticosteroids on Plasma Cortisol Concentrations in Healthy Adults Ronald Brus, MD ORIGINAL INVESTIGATION Background: Recent studies suggest that inhaled corticosteroids may
More informationValue of measuring serum angiotensin I converting enzyme and serum lysozyme in the
Value of measuring serum angiotensin I converting enzyme and serum lysozyme in the management of sarcoidosis C W G TURTON,1 GRUNDY,2 G FIRTH,2 D MITCHLL,' B G RIGDN,2 AND M TURNR-WARWICK' Thorax, 1979,
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationThe clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2012; 29; 119-127 Mattioli 1885 The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large
More informationHealth technology Four treatments for patients with persistent symptoms of asthma were examined:
Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Andersson F, Stahl E, Barnes P J, Lofdahl C G, O'Byrne P M, Pauwels R A, Postma D S, Tattersfield A E, Ullman
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationStudy of Clara cell protein 10, krebs von den lungen 6, and surfactant protein D in serum as disease markers in pulmonary sarcoidosis
CHAPTER 3 Study of Clara cell protein 10, krebs von den lungen 6, and surfactant protein D in serum as disease markers in pulmonary sarcoidosis R. Janssen H. Sato J.C. Grutters A.M. Bernard H. van Velzen-Blad
More informationPulmonary Sarcoidosis - Radiological Evaluation
Original Research Article Pulmonary Sarcoidosis - Radiological Evaluation Jayesh Shah 1, Darshan Shah 2*, C. Raychaudhuri 3 1 Associate Professor, 2 1 st Year Resident, 3 Professor and HOD Radiology Department,
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynergy Respiratory Care Dr. Lyle Melenka
1 2 Synergy Respiratory Care Dr. Lyle Melenka Respiratory Care 2 Accredited Pulmonary Function Labs Cardiac Care 2 Accredited Cardiac Exercise Stress Testing labs WoW Wellness of Workers Early Identification
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationRapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD.
Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD WWW.chestjournal.org Background: Current reviews on the use of inhaled corticosteroids (ICS) for acute asthma underestimated
More informationFERRING PHARMACEUTICALS. Enjoy The simple COR/939/2014/CH3
Enjoy The simple pleasures of life COR/939/2014/CH3 Ulcerative colitis disrupts the simple pleasures in life Patients with ulcerative colitis may live with a considerable symptom burden despite medical
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationPaediatric Public Assessment Report EU Work sharing Procedure - Assessment of Paediatric data. Pulmicort Turbuhaler. Powder for inhalation.
Paediatric Public Assessment Report EU Work sharing Procedure - Assessment of Paediatric data Pulmicort Turbuhaler Powder for inhalation 100 µg, 200 µg, 400 µg Budesonide Marketing Autorisation Holder:
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationInfluence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern
ORIGINAL ARTICLE Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern Tetsuro Sawata, Masashi Bando, Masayuki Nakayama, Naoko Mato, Hideaki Yamasawa
More informationSerum beta-2-microglobulin and angiotensinconverting enzyme activity in sarcoidosis
Thorax 1982;37:936-94 Serum beta-2- and angiotensinconverting enzyme activity in sarcoidosis RW PARRISH, JD WILLIAMS, BH DAVIES From Liandough Hospital, Penarth, South Glamorgan ABSTRACr Angiotensin-converting
More informationSarcoidosis and Uveitis
Sarcoidosis and Uveitis Nicholas Jones Royal Eye Hospital Manchester, UK Sarcoidosis a multisystem chronic inflammation causing multifocal non-caseating granulomas BUT Diagnosis often made indirectly (without
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More information